For Healthcare Professionals Outside the US
For Healthcare Professionals Outside the US
There was no statistical difference between the two treatment arms in time to 10% deterioration (TTD) in EORTC QLQ-C30 global health/QoL status (HR=1.03; 95% CI, 0.72-1.48)*
PIQRAY + fulvestrant delayed median TTC by 8.5 months vs placebo + fulvestrant (23.3 months vs 14.8 months; HR=0.72 [95% CI, 0.54-0.95]) which is meaningful to patients